Moik et al reported risk factors for arterial and venous thromboemboli in a cancer patient treated with an immune checkpoint inhibitor. These can help to identify a patient who may benefit from interventions to reduce the risk. The authors are from Comprehensive Cancer Center Vienna, Medical University of Vienna, and Sechenov University (Moscow).
Patient selection: cancer patient receiving an immune checkpoint inhibitor.
Cumulative incidence: 12.9% for venous and 1.8% for arterial thromboembolism.
Risk factors for thromboembolism:
(1) history of venous thromboembolism (subdistribution HR 3.7)
(2) distant metastases (subdistribution HR 1.7, with p 0.303)
If a venous thromboembolism occurs, then the patient is at increased risk for mortality.
Thromboembolism was not a cause for discontinuation of immune checkpoint inhibitor therapy. Discontinuation followed evidence of disease progression or immune-related adverse events.
To read more or access our algorithms and calculators, please log in or register.
